ArticleScientific reports2020
Risk stratification for early-onset fetal growth restriction in women with abnormal serum biomarkers: a retrospective cohort study.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Brain sparing in fetal growth restriction: The double-edged sword of fetal hypoxaemia.The Journal of physiology · 2026Review
- Sex-specific placental adaptations associated with fetal growth restriction: a review.Journal of animal science · 2026Review
- Article
- Development of non-invasive biomarkers for pre-eclampsia through data-driven cardiovascular network models.Scientific reports · 2024Article
- Clinical value of prenatal screening markers in early pregnancy combined with perinatal characteristics to predict fetal growth restriction.Translational pediatrics · 2024Article
- Phenotype of early-onset fetal growth restriction in sheep.Frontiers in endocrinology · 2024Article
- Growth Velocities Across Distinct Early Life Windows and Child Cognition: Insights from a Contemporary US Cohort.The Journal of pediatrics · 2023Article
- Does fetal growth restriction induce neuropathology within the developing brainstem?The Journal of physiology · 2023Review
- Maternal PlGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction.The Journal of clinical investigation · 2023Article
- Endothelial colony forming cell administration promotes neurovascular unit development in growth restricted and appropriately grown fetal lambs.Stem cell research & therapy · 2023Article
- Effects of currently used marine antifouling paint biocides on green fluorescent proteins in Anemonia viridis.Journal of fluorescence · 2022Article
- The Update of Fetal Growth Restriction Associated with Biomarkers.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2022Review
- The impact of COVID-19 on pregnancy outcomes in a diverse cohort in England.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal maternal serum biomarkers (AMSB), identified through the aneuploidy screening programme, are frequent incidental findings in pregnancy. They are associated with fetal growth restriction (FGR), but previous studies have not examined whether this association is with early-onset (< 34 weeks) or late-onset (> 34 weeks) FGR; as a result there is no consensus on management. The aims of this study were to determine the prevalence and phenotype of FGR in women with AMSB and test the predictive value of placental sonographic screening to predict early-onset FGR. 1196 pregnant women with AMSB underwent a 21-24 week "placental screen" comprising fetal and placental size, and uterine artery Doppler. Multivariable regression was used to calculate a predictive model for early-onset FGR (birthweight centile < 3rd/< 10th with absent umbilical end-diastolic flow, < 34 weeks). FGR prevalence was high (10.3%), however early-onset FGR was uncommon (2.3%). Placental screening effectively identified early-onset (area under the curve (AUC) 0.93, 95% confidence interval (CI) 0.87-1.00), but not late-onset FGR (AUC 0.70, 95% CI 0.64-0.75). Internal validation demonstrated robust performance for detection/exclusion of early-onset FGR. In this cohort, utilisation of our proposed algorithm with targeted fetal growth and Doppler surveillance, compared with universal comprehensive surveillance would have avoided 1044 scans, potentiating significant cost-saving for maternity services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.